Resources from the same session
372O - Balstilimab (bal) alone or with zalifrelimab (zal) treatment for cervical cancer: An open-label, non-comparative, randomised, phase II trial
Presenter: Jusheng An
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
373O - First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) ± bevacizumab (BEV) for recurrent or metastatic cervical cancer (r/mCC): Updated results of the phase II DUBHE-C-204 study
Presenter: Danbo Wang
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 372O and 373O
Presenter: David SP Tan
Session: Proffered Paper session: Gynaecological cancers
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session: Gynaecological cancers
Resources:
Webcast
374O - The burden and trends of gynecological cancers in Asia from 1980 to 2021: A systematic analysis for the global burden of disease study 2021
Presenter: Run Miao
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
375O - DIsease burden and treatment pattern of Recurrent or advanced Endometrial cancer in Korea: A naTIONwide database (DIRECTION) study
Presenter: Hyun-woong Cho
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session: Gynaecological cancers
Resources:
Webcast